Compass Therapeutics, Inc. (CMPX) is a Healthcare stock trading at $2.40 (as of 2026-08-21), with a market capitalization of $431.31M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. It develops antibody-based therapeutics, including clinical candidates such as bispecific antibodies targeting Delta-like ligand 4/Notch and VEGF-A signaling, CD137, and PD-1/PD-L1, to treat human diseases.
Understand Compass Therapeutics, Inc.: how it makes money
Compass Therapeutics develops clinical-stage, oncology-focused antibody-based therapeutics, and (based on the only disclosed revenue category) it makes money through license milestone payments.
For this clinical-stage biopharma, the profit engine is tied to achieving and monetizing development milestones via license payments (not ongoing commercial product sales, as reflected by the disclosed revenue category).
Revenue by segment (latest quarter)
Milestone
$0.0B
Business quality (Weak): The company is still in clinical development, and the most decision-relevant signals appear to come from trial readouts and enrollment, while reported revenue is currently limited to milestone-type licensing.
Bull case
Efficacy signals across defined trial readouts: Reported pooled overall survival for all patients (8.9), overall response rate for Tevesimab plus Paclitaxel (17.1 percent), and radiographic progression rates that show lower progression in the Tevesimab plus Paclitaxel arm versus the Paclitaxel control arm (16.2 percent vs 42.1 percent at week eight).
Companion study scale and follow-up are tracked: Companion 002 includes 168 patients enrolled with a median follow-up of 17, alongside a reported pooled overall survival for Companion 002 (20.0).
Early pipeline progress is quantified in additional programs: CTX8371 is described with patients treated in the first four dosing cohorts (12) and a reported clinical benefit rate in non-small cell lung cancer (60 percent), plus an overall reduction in risk of disease progression (56 percent).
Bear case
No disclosed revenue in the latest reported period: For the period ended 2025-03-31, revenue is 0.0 and the only listed revenue candidate is license revenue from a milestone payment (also 0.0).
Heavy operating losses typical of early-stage development: Operating margin is reported as -1382.0 for the period ended 2025-03-31.
Trial metrics may not translate into approvals or durable benefit: Reported KPIs are specific to pooled and/or defined arms and endpoints (including week eight progression and other trial-specific measures). These signals may not be sufficient on their own to support regulatory approval or long-term outcomes.